Patent: 8,968,719
✉ Email this page to a colleague
Summary for Patent: 8,968,719
Title: | Live, oral vaccine for protection against Shigella dysenteriae serotype 1 |
Abstract: | The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making. |
Inventor(s): | Kopecko; Dennis J. (Silver Spring, MD), Xu; De-Qi (Columbia, MD) |
Assignee: | The United States of America, as represented by the Secretary, Department of Health and Human Sevices (Rockville, MD) |
Application Number: | 14/145,104 |
Patent Claims: | see list of patent claims |
Details for Patent 8,968,719
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Emergent Travel Health, Inc. | VIVOTIF | typhoid vaccine live oral ty21a | Capsule | 103123 | 12/15/1989 | ⤷ Try a Trial | 2024-05-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |